Table 2 Percentage/number of LDDs for CTVs and OARs and the number of verification or cumulative doses evaluated for each structure
CTV | OAR | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Boost D95% | Breast/CW D95% | Axilla D95% | SCV D95% | IMN D95% | Ipsi-lung V40% | Esophagus D0.01cc | Heart mean | ||||
All patients | V-CT versus P-CT doses | With mask | LDD (%) | 0.0 | 0.0 | 1.2 | 3.9 | 8.2 | 5.7 | 8.2 | 1.0 |
V-CT (#) | 63 | 105 | 82 | 77 | 73 | 105 | 73 | 96 | |||
No mask | LDD (%) | 6.7 | 1.5 | 7.3 | 16.7 | 20.8 | 31.8 | 27.3 | 0.0 | ||
V-CT (#) | 15 | 66 | 55 | 60 | 53 | 66 | 55 | 65 | |||
Breast patients | V-CT versus P-CT doses | With mask | LDD (%) | 0.0 | 0.0 | 2.0 | 6.8 | 10.0 | 6.0 | 7.1 | 0.0 |
V-CT (#) | 42 | 68 | 50 | 44 | 40 | 67 | 42 | 61 | |||
No mask | LDD (%) | 10.0 | 0.0 | 11.8 | 17.6 | 40.0 | 23.8 | 23.5 | 0.0 | ||
V-CT (#) | 10 | 21 | 17 | 17 | 15 | 21 | 17 | 20 | |||
CW patients | V-CT versus P-CT doses | With mask | LDD (%) | 0.0 | 0.0 | 0.0 | 0.0 | 6.1 | 5.3 | 9.7 | 2.8 |
V-CT (#) | 21 | 37 | 32 | 33 | 33 | 38 | 31 | 36 | |||
No mask | LDD (%) | 0.0 | 2.2 | 5.3 | 16.3 | 13.2 | 35.6 | 28.9 | 0.0 | ||
V-CT (#) | 5 | 45 | 38 | 43 | 38 | 45 | 38 | 45 | |||
Patients with at least 3 V-CTs | V-CT versus P-CT doses | With mask | LDD (%) | 0.0 | 0.0 | 0.0 | 3.3 | 7.7 | 11.8 | 6.7 | 0.0 |
V-CT (#) | 31 | 34 | 30 | 30 | 26 | 34 | 30 | 30 | |||
No mask | LDD (%) | 16.7 | 2.3 | 7.5 | 20.0 | 22.5 | 25.6 | 22.5 | 0.0 | ||
V-CT (#) | 6 | 43 | 40 | 45 | 40 | 43 | 40 | 43 | |||
Cum versus planned doses | With mask | LDD (#) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | |
V-CT (#) | 8 | 9 | 8 | 8 | 7 | 9 | 8 | 8 | |||
No mask | LDD (#) | 1 | 0 | 1 | 2 | 3 | 4 | 1 | 0 | ||
V-CT (#) | 2 | 13 | 12 | 12 | 12 | 13 | 12 | 13 | |||